Comparison two methods of treatment of mouth ulcer in childhood cancer patients study design: Randomized parallel trial
| ISRCTN | ISRCTN17793029 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17793029 |
| Protocol serial number | N/A |
| Sponsor | Hospital Universiti Sains Malaysia |
| Funder | Hospital Universiti Sains Malaysia |
- Submission date
- 11/08/2015
- Registration date
- 07/10/2015
- Last edited
- 18/04/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Oral Health
Plain English summary of protocol
Background and study aims
Chemotherapy is a type of cancer treatment which works by killing the cancer cells so that they can’t spread. Although it is an effective cancer treatment, it does have side effects. The drugs used in chemotherapy cannot distinguish between the fast-growing cancer cells and healthy types of fast-growing cells in the body. One of the most common cells affected are part of the mucous membrane, in a condition known as mucositis. The mucous membrane acts to line the parts of the body which come into contact with air, such as in the mouth and digestive system (gastrointestinal tract). Oral mucositis is the most common type of mucositis in cancer patients, and can lead to a number of problems, such as mouth ulcers, pain, increased risk of infection and nutritional problems due to difficulty swallowing. There are a number of ways to help treat patients suffering from oral mucositis. This study aims to compare how effective an oral aid gel (zytee) which is used to treat mouth ulcers, with taking granulocyte-colony stimulating factor (GCSF) which helps to increase the number of white blood cells that are released into the blood, helping to fight infection.
Who can participate?
Children with cancer, on chemotherapy treatment with oral mucositis.
What does the study involve?
Participants are randomly divided into one of two groups. The first group are treated with the oral aid (zytee gel), and the second group are treated with granulocyte-colony stimulating factor (GCSF), which is taken in oral form.
What are the possible benefits and risks of participating?
Possible benefits of participating are increasing knowledge about oral health, as well as patients receiving treatment free of charge. There are no risks of participating in the study,
Where is the study run from?
Hospital Universiti Sains Malaysia (Malaysia)
When is the study starting and how long is it expected to run for?
April 2013 to April 2016
Who is funding the study?
Hospital Universiti Sains Malaysia (Malaysia)
Who is the main contact?
Dr Malid Alshannuki
Contact information
Scientific
Lot pt 1207 Bandar Baru
Kota Bharu
16150
Malaysia
 ORCID ID |
0000-0003-2926-7449 |
|---|
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Single-centre randomized parallel trial |
| Secondary study design | Randomised parallel trial |
| Scientific title | Randomized controlled trial of oral GCSF versus oral aid for treating oral mucositis in patients with childhood cancer receiving chemotherapy |
| Study objectives | There are significance differences of the outcomes of treating oral mucositis between oral GCSF and oral aid groups . |
| Ethics approval(s) | Ethics Committee at Universiti Sains Malaysia, ref: USMKK/PPP/JEPeM[261.3(16)] |
| Health condition(s) or problem(s) studied | Oral mucositis |
| Intervention | Medication (routinely used in the pediatric Oncology ward in HUSM) will be given three times daily (morning, evening, and night) until the oral mucositis resolved. Block randomization will be used for randomization.The basic idea of block randomization is to divide potential patients into m blocks of size2n, randomize each block such that n patients are allocated to A and n to B ,then choose the blocks randomly.This method ensures equal treatment allocation within each block if the complete block is used.Example: Two treatments of A, B and Block size of 2 x 2= 4 Group A: Oral aid (zytee) Composition: Choline salicylate and benzalkonium chloride. Group B : Oral granulocyte colony stimulating factor GCSF (0 .1ml). Possible treatment allocations within each block are: 1. AABB 2. BBAA 3. ABAB 4. BABA 5. ABBA 6. BAAB |
| Intervention type | Drug |
| Phase | |
| Drug / device / biological / vaccine name(s) | 1. Oral aid (zytee) Composition: Choline salicylate and benzalkonium chloride 2. GCSF (granulocyte colony stimulating factor) |
| Primary outcome measure(s) |
Primary outcomes as of 18/04/2017: |
| Key secondary outcome measure(s) |
Secondary outcome as of 18/04/2017: |
| Completion date | 01/04/2016 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Lower age limit | 3 Years |
| Upper age limit | 12 Years |
| Sex | All |
| Target sample size at registration | 76 |
| Key inclusion criteria | 1. Aged 3-12 years 2. Have oral mucositis 3. On chemotherapy treatment |
| Key exclusion criteria | 1. Other causes of oral ulcer such as trauma and CT disease 2. Cancer patient who is not under chemotherapy |
| Date of first enrolment | 01/04/2013 |
| Date of final enrolment | 01/04/2016 |
Locations
Countries of recruitment
- Malaysia
Study participating centre
Kelantan
Kota Bharu
16150
Malaysia
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
18/04/2017: The outcome measures have been updated.
